News
PSNL
13.02
+2.86%
0.36
Merck's Bio-Techne buyout put Life Sciences sector in focus: top quant-rated stocks
Seeking Alpha · 1d ago
Weekly Report: what happened at PSNL last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at PSNL last week (0608-0612)?
Weekly Report · 06/15 10:22
Caris Life Sciences: The Discount To Peers Looks Hard To Ignore
Seeking Alpha · 06/12 11:57
Personalis’ specimen collection kits obtain European Union CE-IVD mark
TipRanks · 06/09 10:45
Personalis Wins EU Compliance Mark for Cancer Testing Blood Kits, Blood Collection Kits Receive European Diagnostic Mark
Benzinga · 06/09 10:06
Personalis blood collection kits win EU CE-IVD mark under IVDR
PUBT · 06/09 10:00
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Barchart · 06/09 05:00
Weekly Report: what happened at PSNL last week (0601-0605)?
Weekly Report · 06/08 10:18
Personalis CFO, COO Aaron Tachibana disposes of common shares worth $480,400
PUBT · 06/06 00:20
Personalis Highlights Cancer-Detection Data Across Multiple Tumor Types
Benzinga · 06/02 10:17
Personalis NeXT Personal MRD test posts 100% sensitivity for colorectal cancer relapse in VICTORI study at ASCO 2026
PUBT · 06/02 10:01
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Barchart · 06/02 05:00
Weekly Report: what happened at PSNL last week (0525-0529)?
Weekly Report · 06/01 10:22
Personalis CEO Christopher M. Hall disposes of common shares worth $1,101,800.18
PUBT · 05/30 00:45
Personalis CFO, COO Aaron Tachibana disposes of common shares valued at $449,248.42
PUBT · 05/30 00:27
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating
Seeking Alpha · 05/28 21:14
Thursday's ETF Movers: ARKG, XES
NASDAQ · 05/28 18:32
Personalis to Present New Cancer Detection Data at Major Oncology Conference
Benzinga · 05/26 10:07
Personalis NeXT Personal ctDNA assay posts 100% longitudinal sensitivity for colorectal cancer recurrence in VICTORI study
PUBT · 05/26 10:00
More
Webull provides a variety of real-time PSNL stock news. You can receive the latest news about Personalis through multiple platforms. This information may help you make smarter investment decisions.
About PSNL
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.